The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC
Status:
Terminated
Trial end date:
2021-01-08
Target enrollment:
Participant gender:
Summary
Study the effect of metformin when added to definitive locoregional radiotherapy on
locoregional control and relapse rate in stage III non-small cell lung cancer patients
receiving sequential chemoradiotherapy. Try to identify subsets of patients who derive
maximum benefit of adding metformin to radiotherapy using innovative biomarkers.